Patient Perspectives on Pharmacotherapy of Alcohol
                    Dependence

Julian Wellensiek; Michael Specka; Johannes Just; Markus Banger; Udo Bonnet; Norbert Scherbaum

doi:10.1055/a-2190-4842

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2024; 57(01): 21-29
DOI: 10.1055/a-2190-4842

Original Paper

Patient Perspectives on Pharmacotherapy of Alcohol Dependence

Julian Wellensiek

¹LVR Hospital Bonn, Department of Addiction Disorders and Psychotherapy, Bonn, Germany

,

Michael Specka

²LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany

,

Johannes Just

³Witten/Herdecke University, Faculty of Health, Department of Medicine, Witten, Germany

,

Markus Banger

¹LVR Hospital Bonn, Department of Addiction Disorders and Psychotherapy, Bonn, Germany

,

Udo Bonnet

²LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany

⁴Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Castrop-Rauxel, Germany

,

Norbert Scherbaum

²LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany

› Author Affiliations

Abstract

Introduction Pharmacotherapy with drugs like naltrexone or acamprosate is a well-evaluated element in the treatment of alcohol dependence (AD). However, in many countries, these medications are rarely administered. The objective of the present study was to identify from patients’ perspective factors that prevent the initiation and compliance with pharmacological treatment of AD.

Methods Patients from inpatient alcohol withdrawal treatment underwent a standardized interview. Questions included socio-demographic data, history of AD, treatment history, knowledge and personal experience regarding pharmacotherapy of AD, and personal views about the causes of AD.

Results Three hundred patients (mean age 47.3 years, 27.7% female, mean duration of AD 8.9 years, 67% with a history of previous inpatient withdrawal treatment) were included. The majority of patients (58.7%) already knew drugs for the pharmacotherapy of AD. Thirty percent had ever used such medications, most often acamprosate. Except for disulfiram, pharmacotherapy of AD had lasted only a few weeks, on average. Medication usually had been applied without additional psychotherapy. No severe side effects were reported. Patients had often stopped pharmacotherapy on their own, when assuming they had reached stable abstinence. Openness to start pharmacotherapy for AD was currently stated by 67% of the total sample. In multiple logistic regression, openness was predicted by having a concept of AD as a medical disease and by a shorter duration of AD.

Discussion To improve the administration of pharmacotherapy for AD implementation strategies should be systematically developed and evaluated with a focus on the concept of AD as a medical disease.

Key words

alcohol dependence - pharmacotherapy - anti-craving substances - disulfiram - patient perspective

Full Text

References

References
1 Carvalho AF, Heilig M, Perez A. et al. Alcohol use disorders. Lancet 2019; 394: 781-792
2 Soyka M, Kranzler HR, Hesselbrock V. et al. Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World J Biol Psychiatry 2017; 18: 86-119
3 Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: A review. JAMA 2018; 320: 815-824
4 Jonas DE, Amick HR, Feltner C. et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 2014; 311: 1889-1900
5 Castrén S, Mäkelä N, Alho H. Selecting an appropriate alcohol pharmacotherapy: Review of recent findings. Curr Opin Psychiatry 2019; 32: 266-274
6 Heikkinen M, Taipale H, Tanskanen A. et al. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients. Addiction 2021; 116: 1990-1998
7 Krampe H, Stawicki S, Wagner T. et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30: 86-95
8 Han B, Jones C, Einstein EB. et al. Use of medications for alcohol use disorder in the US: Results from the 2019 National Survey on Drug Use and Health (Letter). JAMA Psychiatry 2021; 78: 922-924
9 Fairbanks J, Umbreit A, Kolla BP. et al. Evidence-based pharmacotherapies for alcohol use disorder: Clinical pearls. Mayo Clin Proc 2020; 95: 1964-1977
10 Scherbaum N, Holzbach R, Stammen G. et al. Very low frequency of drug therapy of alcohol dependence in Germany - Analysis of data of a statutory health insurance. Pharmacopsychiatry 2020; 53: 37-39
11 Wallhed Finn S, Lundin A, Sjöqvist H. et al. Pharmacotherapy for alcohol use disorders - Unequal provision across sociodemographic factors and co-morbid conditions. A cohort study of the total population in Sweden. Drug Alcohol Depend 2021; 227: 108964
12 Kim Y, Hack LM, Ahn ES. et al. Practical outpatient pharmacotherapy for alcohol use disorder. Drugs Context 2018; 7: 1-14
13 Knox J, Hasin DS, Larson FRR. et al. Prevention, screening and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry 2019; 6: 1054-1067
14 Gregory C, Chorny Y, McLeod SL. et al. First-line medications for the outpatient treatment of alcohol use disorder: A systematic review of perceived barriers. J Addict Med 2022; 16: e210-e218
15 Mark TL, Kranzler HR, Song X. et al. Physicians’ opinions about medications to treat alcoholism. Addiction 2003; 98: 617-626
16 Mark TL, Kranzler HR, Poole VH. et al. Barriers to the use of medications to treat alcoholism. Am J Addict 2003; 12: 281-294
17 Scheurich A, Müller MJ, Wetzel H. et al. Reliability and validity of the German version of the European Addiction Severity Index (EuropASI). J Stud Alcohol 2000; 61: 916-918
18 Crawford J, Heather N. Public attitudes to the disease concept of alcoholism. Int J Addict 1987; 22: 1129-1138
19 Arbeitsgemeinschaft medizinischer Fachgesellschaften (AWMF). S3-Leitlinie – Screening, diagnose und behandlung alkoholbezogener störungen [Highest quality level guideline: Screening, diagnosis and treatment of alcohol–related disorders]. Online: https://www.awmf.org/leitlinien/detail/II/076-001.html, accessed May 10, 2023
20 Peduzzi P, Concato J, Kemper E. et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-1379 PMID: 8970487
21 Bauer U, Hasenöhrl A. Therapieerfolg Alkoholabhängiger nach qualifizierter entzugsbehandlung und konventioneller Entgiftung [Success of alcohol dependents after comprehensive withdrawal treatment or conventional detoxification treatment]. SUCHT 2000; 46: 250-259
22 Rittenberg A, Hines AL, Alvanzo AAH. et al. Correlates of alcohol use disorder pharmacotherapy receipt in medically insured patients. Drug Alcohol Depend 2020; 214: 10817410
23 Zimmermann M, Papa A. Causal explanations of depression and treatment credibility in adults with untreated depression: Examining attribution theory. Psychol Psychother 2020; 93: 537-554
24 Probst C, Manthey J, Martinez A, Rehm J. Alcohol use disorder severity and reported reasons not to seek treatment: A cross-sectional study in European primary care practices. Subst Abuse Treat Prev Policy 2015; 10: 32
25 Rehm J, Allamani A, Elekes Z. et al. Alcohol dependence and treatment utilization in Europe - A representative cross-sectional study in primary care. BMC Fam Pract 2015; 16: 90
26 Australian National Survey of Mental H, Wellbeing. Proudfoot H, Teesson M. Who seeks treatment for alcohol dependence? Findings from the Australian National Survey of mental health and wellbeing. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 451-456
27 Rombouts SA, Conigrave JH, Saitz R. et al. Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: A systematic review. BMC Fam Pract 2020; 21: 260
28 Oliva EM, Maisel NC, Gordon AJ. et al. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep 2011; 13: 374-381
29 Mark TL, Kranzler HR, Poole VH. et al. Barriers to the use of medications to treat alcoholism. Am J Addict 2003; 12: 281-294
30 Haley SJ, Pinsker EA, Gerould H. et al. Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings. Subst Abus 2019; 40: 501-509
31 Verthein U, Kuhn S, Gabriel K. et al. Die behandlung des alkoholentzugs mit oxazepam oder clomethiazol – eine naturalistische beobachtungsstudie [Treatment of alcohol withdrawal syndrome with oxazepam or clomethiazole - A naturalistic observational study]. Psychiatr Prax 2018; 45: 95-102
32 Reichl D, Enewoldsen N, Weisel KK. et al. Association of impulsivity with quality of life and well-being after alcohol withdrawal treatment. J Clin Psychol 2022; 78: 1451-1462